Clinical Trials
63 trialsTesting the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
EPIK-B3
Novartis
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
LEAP-005
Merck Sharp & Dohme LLC
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
BEGONIA
AstraZeneca
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Memorial Sloan Kettering Cancer Center
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
AstraZeneca
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
KEYLYNK-009
Merck Sharp & Dohme LLC
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
OPALESCENCE
Institut Cancerologie de l'Ouest
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
INTEGRAL
The Methodist Hospital Research Institute
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
neoMono
Palleos Healthcare GmbH
EL1SSAR
Hoffmann-La Roche
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Seagen Inc.
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
A Study of PF-06873600 in People With Cancer
Pfizer
IMpassion132
Hoffmann-La Roche
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
MK-5890-001
Merck Sharp & Dohme LLC
ELEVATE TNBC
Gilead Sciences